Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2009

01-08-2009 | Brief Report

Nationwide surveillance of antimicrobial resistance among Haemophilus influenzae and Streptococcus pneumoniae in intensive care units in Taiwan

Authors: S.-S. Jean, P.-R. Hsueh, W.-S. Lee, H.-T. Chang, M.-Y. Chou, I.-S. Chen, J.-H. Wang, C.-F. Lin, J.-M. Shyr, W.-C. Ko, J.-J. Wu, Y.-C. Liu, W.-K. Huang, L.-J. Teng, C.-Y. Liu

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2009

Login to get access

Abstract

A nationwide susceptibility surveillance of Streptococcus pneumoniae and Haemophilus influenzae isolates collected from patients treated at the intensive care units (ICUs) of ten Taiwanese major teaching hospitals was conducted from September 2005 through November 2005. High rates of resistance (intermediate/resistant) of S. pneumoniae to penicillin (85% resistance), ceftriaxone (46%/20%), and cefepime (43%/15%) by meningitis criteria, and in contrast, non-susceptibilities (intermediate/resistant) to penicillin (0%/0%), ceftriaxone (20%/0%) and cefepime (15%/0%) by non-meningitis criteria were noted (p values < 0.05) by the Clinical and Laboratory Standards Institute 2008. Resistant rate of S. pneumoniae to azithromycin was also high (63%). S. pneumoniae isolates were significantly more susceptible to ertapenem (87%) than to imipenem (39%) and meropenem (44%) (p values < 0.05). Rates of non-susceptibilities of H. influenzae isolates to ampicillin and cefaclor were high (55% and 45%, respectively). No β-lactamase-negative ampicillin-resistant (BLNAR) H. influenzae isolates were found. Imipenem has a notably higher MIC90 value (8 μg/ml) for H. influenzae than that of the other two carbapenems. Tigecycline showed good in vitro activities against these two respiratory pathogens. High rates of resistance among isolates of S. pneumoniae and H. influenzae continue to exist in the ICUs of Taiwan.
Literature
1.
go back to reference Lau YJ, Hsueh PR, Liu YC, Shyr JM, Huang WK, Teng LJ, Liu CY, Luh KT (2006) Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan. Microb Drug Resist 12:130–135. doi:10.1089/mdr.2006.12.130 PubMedCrossRef Lau YJ, Hsueh PR, Liu YC, Shyr JM, Huang WK, Teng LJ, Liu CY, Luh KT (2006) Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan. Microb Drug Resist 12:130–135. doi:10.​1089/​mdr.​2006.​12.​130 PubMedCrossRef
2.
go back to reference Hsueh PR, Liu YC, Yang D, Yan JJ, Wu TL, Huang WK, Wu JJ, Ko WC, Leu HS, Yu CR, Luh KT (2001) Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Microb Drug Resist 7:373–382. doi:10.1089/10766290152773383 PubMedCrossRef Hsueh PR, Liu YC, Yang D, Yan JJ, Wu TL, Huang WK, Wu JJ, Ko WC, Leu HS, Yu CR, Luh KT (2001) Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Microb Drug Resist 7:373–382. doi:10.​1089/​1076629015277338​3 PubMedCrossRef
3.
go back to reference CLSI (2005) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edn. Approved standard M7-A6. Clinical and Laboratory Standards Institute, Wayne, PA, USA CLSI (2005) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edn. Approved standard M7-A6. Clinical and Laboratory Standards Institute, Wayne, PA, USA
4.
go back to reference CLSI (2008) Performance standards for antimicrobial susceptibility testing, 15th informational supplement. Supplemental tables M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA, USA CLSI (2008) Performance standards for antimicrobial susceptibility testing, 15th informational supplement. Supplemental tables M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA, USA
5.
go back to reference Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A, Active Bacterial Core Surveillance Program of the Emerging Infections Program Network (2000) Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 343:1917–1924. doi:10.1056/NEJM200012283432603 PubMedCrossRef Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A, Active Bacterial Core Surveillance Program of the Emerging Infections Program Network (2000) Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 343:1917–1924. doi:10.​1056/​NEJM200012283432​603 PubMedCrossRef
6.
go back to reference Hilliard NJ, Johnson CN, Armstrong SH, Quarles S, Waites KB (2002) In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. Int J Antimicrob Agents 20:136–140. doi:10.1016/S0924-8579(02)00129-2 PubMedCrossRef Hilliard NJ, Johnson CN, Armstrong SH, Quarles S, Waites KB (2002) In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. Int J Antimicrob Agents 20:136–140. doi:10.​1016/​S0924-8579(02)00129-2 PubMedCrossRef
8.
go back to reference Cerquetti M, Giufrè M, Cardines R, Mastrantonio P (2007) First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates. Antimicrob Agents Chemother 51:3155–3161. doi:10.1128/AAC.00335-07 PubMedCrossRef Cerquetti M, Giufrè M, Cardines R, Mastrantonio P (2007) First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates. Antimicrob Agents Chemother 51:3155–3161. doi:10.​1128/​AAC.​00335-07 PubMedCrossRef
9.
go back to reference Hardy DJ, Swanson RN, Rode RA, Marsh K, Shipkowitz NL, Clement JJ (1990) Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 34:1407–1413PubMed Hardy DJ, Swanson RN, Rode RA, Marsh K, Shipkowitz NL, Clement JJ (1990) Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 34:1407–1413PubMed
10.
go back to reference Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST Program) Group (2005) In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 52:215–227. doi:10.1016/j.diagmicrobio.2005.06.001 PubMedCrossRef Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST Program) Group (2005) In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 52:215–227. doi:10.​1016/​j.​diagmicrobio.​2005.​06.​001 PubMedCrossRef
Metadata
Title
Nationwide surveillance of antimicrobial resistance among Haemophilus influenzae and Streptococcus pneumoniae in intensive care units in Taiwan
Authors
S.-S. Jean
P.-R. Hsueh
W.-S. Lee
H.-T. Chang
M.-Y. Chou
I.-S. Chen
J.-H. Wang
C.-F. Lin
J.-M. Shyr
W.-C. Ko
J.-J. Wu
Y.-C. Liu
W.-K. Huang
L.-J. Teng
C.-Y. Liu
Publication date
01-08-2009
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2009
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-009-0727-3

Other articles of this Issue 8/2009

European Journal of Clinical Microbiology & Infectious Diseases 8/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.